Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF 2 /HO-1 signaling

被引:0
作者
Sleem, M. [1 ]
Aboubakr, E. M. [1 ]
Mohamed, W. R. [2 ]
Messiha, B. A. S. [2 ]
Taye, A. [1 ]
机构
[1] South Valley Univ, Fac Pharm, Dept Pharmacol & Toxicol, Qena 83523, Egypt
[2] Beni Suef Univ, Dept Pharmacol & Toxicol, Fac Pharm, Beni Sueif, Egypt
来源
PHARMAZIE | 2024年 / 79卷 / 06期
关键词
HIGH-FAT DIET; RECEPTOR AGONIST LIXISENATIDE; INDUCED RENAL FIBROSIS; NF-KAPPA-B; OXIDATIVE STRESS; ENDOTHELIAL DYSFUNCTION; INSULIN-RESISTANCE; PROTECTS; ALPHA; HYPERGLYCEMIA;
D O I
10.1691/ph.2024.4509
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, we hypothesized that lixisenatide (LIX) and ticagrelor (TIC) could have a protective effect against type 2 diabetes mellitus (T2DM)-induced vascular damage. Furthermore, we explored the possible additional protective effect of co -administering LIX and TIC in the treatment regimen. Methods: 50 male rats were divided into five groups, each comprising 10 rats: C (control), D (T2DM rats), D + LIX (T2DM rats treated with LIX for 4 weeks), D + TIC (T2DM rats treated with TIC for 4 weeks), and D + LIX + TIC (T2DM rats treated with LIX + TIC for 4 weeks). Results : The D group showed an increase in body weight, blood glucose, hemostatic model assessment for insulin resistance (HOMA-IR), aorta reactive oxygen species (ROS), and nuclear factor kappa B (NF -KB), along with a reduction in serum insulin, aorta superoxide dismutase (SOD), glutathione reduced (GSH), nuclear factor erythroid-2 (NrF 2 ), hemeoxygenase-1 (HO -1), and endothelial nitric oxide synthase (eNOS). Deterioration in the aorta histopathological condition, coupled with a noticeable impairment in vascular reactivity compared to the C group, was observed. A single administration of LIX showed a reduction in body weight, blood glucose, HOMA-IR, aorta ROS, and NF -KB, accompanied by an increase in serum insulin, aorta SOD, GSH, NrF 2 , HO -1, and eNOS. Amelioration in the aorta histopathological condition and improved vascular reactivity compared to the D group were reported. Similarly, a single administration of TIC showed a reduction in aorta ROS and NF -KB, along with an increase in aorta SOD, GSH, NrF 2 , HO -1, and eNOS. A slight amelioration was detected in the aorta histopathological condition, with improved vascular reactivity compared to the D group. The combined administration of LIX and TIC showed a reduction in aorta ROS and NF -KB, along with an increase in aorta GSH, SOD, HO -1, and eNOS. This was combined with evident amelioration in the aorta histopathological condition and noticeable improvement in vascular reactivity compared to the single treatment with either LIX or TIC group. Conclusion : The present study introduces clear evidence that the administration of LIX and TIC can improve metabolic and vascular complications of T2DM through modulating eNOS and NrF 2 /HO-1 signaling. The combined administration of LIX and TIC produced more significant effects than a single treatment.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 82 条
[1]   Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats [J].
Abdel-latif, Rania G. ;
Ahmed, Amira F. ;
Heeba, Gehan H. .
LIFE SCIENCES, 2020, 263
[2]   Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways [J].
Abdel-latif, Rania G. ;
Heeba, Gehan H. ;
Taye, Ashraf ;
Khalifa, Mohamed M. A. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 833 :145-154
[3]   Nrf2 signaling pathway: Pivotal roles in inflammation [J].
Ahmed, Syed Minhaj Uddin ;
Luo, Lin ;
Namani, Akhileshwar ;
Wang, Xiu Jun ;
Tang, Xiuwen .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2017, 1863 (02) :585-597
[4]   Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro [J].
Ahmed, Yasmin Moustafa ;
Messiha, Basim Anwar Shehata ;
El-Sayed El-Daly, Mahmoud ;
Abo-Saif, Ali Ahmed .
PHARMACOLOGICAL REPORTS, 2019, 71 (06) :1034-1043
[5]   Isoliquiritigenin attenuates inflammation and modulates Nrf2/caspase-3 signalling in STZ-induced aortic injury [J].
Alzahrani, Sharifa ;
Said, Eman ;
Ajwah, Sadeem M. ;
Alsharif, Sumayyah Y. ;
El-Bayoumi, Khaled S. ;
Zaitone, Sawsan A. ;
Qushawy, Mona ;
Elsherbiny, Nehal M. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2021, 73 (02) :193-205
[6]   Suppression of type 2 diabetes mellitus-induced aortic ultrastructural alterations in rats by insulin: an association of vascular injury biomarkers [J].
Alzamil, Norah M. ;
Dawood, Amal F. ;
Hewett, Peter W. ;
Bin-Jaliah, Ismaeel ;
Assiri, Abdullah S. ;
Abdel Kader, Dina H. ;
Eid, Refaat A. ;
Haidara, Mohamed A. ;
Al-Ani, Bahjat .
ULTRASTRUCTURAL PATHOLOGY, 2020, 44 (03) :316-323
[7]   Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers A Randomized Crossover Study [J].
Ariotti, Sara ;
Ortega-Paz, Luis ;
van Leeuwen, Maarten ;
Brugaletta, Salvatore ;
Leonardi, Sergio ;
Akkerhuis, K. Martijn ;
Rimoldi, Stefano F. ;
Janssens, Gladys ;
Gianni, Umberto ;
van den Berge, Jan C. ;
Karagiannis, Alexios ;
Windecker, Stephan ;
Valgimigli, Marco .
JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (16) :1576-1586
[8]   Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 [J].
Armstrong, Duncan ;
Summers, Claire ;
Ewart, Lorna ;
Nylander, Sven ;
Sidaway, James E. ;
van Giezen, J. J. J. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 19 (02) :209-219
[9]   Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects [J].
Becker, Reinhard H. A. ;
Stechl, Jens ;
Steinstraesser, Axel ;
Golor, Georg ;
Pellissier, Franck .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 (06) :610-618
[10]   Anesthesia protocol for ear surgery in Wistar rats (animal research) [J].
Bhatia, Abhijeet ;
Saikia, Pranjal Pratim ;
Dkhar, Barilin ;
Pyngrope, Haphidasara .
ANIMAL MODELS AND EXPERIMENTAL MEDICINE, 2022, 5 (02) :183-188